Semifluorinated Alkane Eye Drops for Dry Eye
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ophthalmic compositions for treating dry eye disease and meibomian gland dysfunction often cause visual disturbances, are difficult to manufacture in sterile form, and may contain preservatives that are damaging to the ocular surface, limiting their effectiveness and convenience for patients.
Innovation Solution
A novel composition comprising at least two semifluorinated alkanes, which can be used as a medicine or cleansing solution for the eye, effectively solubilizes obstructive meibum lipids, forms a protective lubricating layer, and is microbiologically stable, reducing the need for preservatives and improving patient convenience.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional ophthalmic compositions are used to treat dry eye disease, then therapeutic effect is achieved, but visual disturbances occur and manufacturing in sterile form becomes difficult
Solution Approach 1:
The patent changes the chemical composition parameters by using semifluorinated alkanes with specific carbon chain lengths (C8-C22) and fluorine content (50-100%), which fundamentally alters the physical properties of the ophthalmic composition. This enables the formulation to achieve therapeutic efficacy while maintaining optical clarity and ease of sterile manufacturing, directly resolving the contradiction between therapeutic effect and visual disturbance.
2Reliability
If preservatives are added to ophthalmic compositions to prevent microbial contamination, then microbiological stability is improved, but damage to the ocular surface occurs
Solution Approach 1:
The semifluorinated alkane composition inherently possesses antimicrobial properties that enable it to protect itself from microbial contamination without requiring additional preservative agents. The composition's unique molecular structure creates an environment that is naturally resistant to microbial growth, thus achieving microbiological stability while eliminating the harmful effects of preservatives on the ocular surface.
3Reliability
If conventional ophthalmic compositions are used, then treatment of dry eye symptoms is provided, but patient convenience is reduced due to preservative damage and visual disturbances
Solution Approach 1:
The patent employs composite material principles by formulating a multi-component system that includes semifluorinated alkanes combined with other compatible ophthalmic ingredients. This composite formulation integrates multiple functions: therapeutic activity for dry eye treatment, inherent antimicrobial protection, and optimal rheological properties for patient comfort and convenience, thereby resolving the contradiction between symptom treatment and patient convenience.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The semifluorinated alkane composition reduces symptom severity of dry eye syndrome by enhancing tear film stability, minimizing evaporation, and providing a clear vision without blurring, while being well-tolerated by the eye and resistant to microbial contamination.
Implementation Method 1
effectively solubilizes obstructive meibum lipids
Implementation Method 2
forms a protective lubricating layer
Implementation Method 3
minimizing evaporation
Data Source
AI summary
The invention provides novel compositions comprising at least two or more semifluorinated alkanes. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue, such as for use in the treatment of keratoconjunctivitis sicca (dry eye) and/or meibomian gland dysfunction and symptoms associated therewith. The invention further provides kits comprising such compositions.